Pharmaceutical composition with improved bioavailability

The invention relates to solid dispersions of poorly water soluble compounds, in particular 4-{[(2R, 3S, 4R, 5S)-4-(4-chloro-2-fluorophenyl)-3-(3-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-pyrrolidine-2-carbonyl]amino}-3-methoxy-benzoic Acid, formed by solvent co-precipitation or spray dr...

Full description

Saved in:
Bibliographic Details
Main Authors SHAH NAVNIT HARGOVINDAS, MA HUA, ZHANG YU-E, LOMUSCIO STEVE, MATCHETT MICHAEL ALLEN, SANDHU HARPREET K
Format Patent
LanguageChinese
English
Published 19.02.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to solid dispersions of poorly water soluble compounds, in particular 4-{[(2R, 3S, 4R, 5S)-4-(4-chloro-2-fluorophenyl)-3-(3-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-pyrrolidine-2-carbonyl]amino}-3-methoxy-benzoic Acid, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds. 本发明涉及通过溶剂共沉淀或喷雾干燥形成的水难溶性化合物，特别是4-{[(2R,3S,4R,5S)-4-(4-氯-2-氟苯基)-3-(3-氯-2-氟苯基)-4-氰基-5-(2,2-二甲基丙基)-吡咯烷-2-羰基]氨基}-3-甲氧基-苯甲酸的固体分散体，其导致所述化合物的改善的生物利用度、安全性和耐受性。
Bibliography:Application Number: CN202011052471